---
title: "GeoVax Q2 FY26 net loss narrows to $4.43 million, or $0.97 a share; revenue posts no revenue"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293972035.md"
description: "GeoVax reported a narrowed Q2 FY26 net loss of $4.43 million ($0.97/share) compared to $5.37 million prior year, with nil revenue due to the termination of the BARDA GEO-CM04S1 contract. R&D expenses decreased to $3.11 million. Cash stood at approximately $3.1 million. The company plans to initiate its pivotal GEO-MVA immunobridging study in Q4 under an expedited EMA pathway while advancing its Gedeptin immuno-oncology program."
datetime: "2026-07-27T20:34:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293972035.md)
  - [en](https://longbridge.com/en/news/293972035.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293972035.md)
---

# GeoVax Q2 FY26 net loss narrows to $4.43 million, or $0.97 a share; revenue posts no revenue

-   GeoVax posted a Q2 net loss of $4.43 million, or $0.97 a share, narrowing from $5.37 million, or $8.74 a year earlier. \* Revenue was nil, versus $852,282 a year earlier after BARDA terminated the GEO-CM04S1 contract for convenience in April 2025. \* R&D expense fell to $3.11 million from $4.73 million on lower costs tied to discontinued BARDA work and reduced GEO-CM04S1 clinical spending. \* Cash was about $3.1 million at June 30, 2026, roughly flat versus Dec. 31, 2025. \* GeoVax expects to start its pivotal GEO-MVA immunobridging study in Q4 under an expedited EMA pathway, while advancing its Gedeptin immuno-oncology program. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GeoVax Labs Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-024522), on July 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [GOVXW.US](https://longbridge.com/en/quote/GOVXW.US.md)
- [GOVX.US](https://longbridge.com/en/quote/GOVX.US.md)

## Related News & Research

- [EMA: Q2 2026 adjusted EPS reached $0.69, with strong cash flow and portfolio optimization completed](https://longbridge.com/en/news/295232708.md)
- [Tinde Sparebank releases Q2 2026 interim report](https://longbridge.com/en/news/295802190.md)
- [Valneva announces availability of H1 2026 financial report](https://longbridge.com/en/news/295822130.md)
- [CitroTech Provides Q2 2026 Business Update in Letter to Shareholders](https://longbridge.com/en/news/295561956.md)
- [Geo Group (NYSE:GEO) Issues Quarterly Earnings Results](https://longbridge.com/en/news/295175523.md)